New drug shows promise for blood cancer control in small japanese study

NCT ID NCT05673460

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 26 times

Summary

This early-phase study tested the safety and tolerability of a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The goal was to see how the body handles the drug and if it can help control the disease. Because patients may need ongoing treatment, this is considered disease control, not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MATURE B-CELL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chiba Cancer Center ( Site 0005)

    Chiba, 260-8717, Japan

  • Kindai University Hospital ( Site 0006)

    Sayama, Osaka, 589-8511, Japan

  • Kyushu University Hospital ( Site 0008)

    Fukuoka, 812-8582, Japan

  • Nagoya University Hospital ( Site 0003)

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital East ( Site 0002)

    Kashiwa, Chiba, 2778577, Japan

  • Okayama University Hospital ( Site 0007)

    Okayama, 700-8558, Japan

  • Yamagata University Hospital ( Site 0001)

    Yamagata, 990-9585, Japan

Conditions

Explore the condition pages connected to this study.